Evaxion to present new phase 2 immune data for EVX-01 melanoma vaccine at SITC 2026

• Evaxion flagged new immune data from its phase 2 EVX-01 personalized cancer vaccine study in advanced melanoma.
• Results will be presented at SITC 2026 in November, following a three-year clinical update scheduled for ESMO on Oct. 24, 2026.
• The readout is expected to show broader immune effects for EVX-01 with pembrolizumab beyond vaccine-specific responses.
• Earlier findings already presented indicated strong, sustained clinical benefit in patients treated with the combination.
• Year-three follow-up will also gauge EVX-01 activity as a stand-alone therapy, informing durability and potential positioning beyond anti-PD-1 use.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evaxion A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610020900OMX_____CNEWS_EN_GNW1001275992_en) on October 02, 2026, and is solely responsible for the information contained therein.